Clinical Trial: Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
Study Status: Completed
Recruit Status: RECRUITING
Condition: Diffuse Glioma
Study Type: INTERVENTIONAL
Official Title: Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501
Brief Summary:
This early phase I trial studies brain tumor (glioma) metabolism in response to eflornithine (DFMO) and polyamine transport inhibitor AMXT-1501 dicaprate (AMXT 1501) in patients with diffused or high grade glioma.Brain tumors use and produce certain molecules to survive and grow.DFMO is an irreversible inhibitor of ornithine decarboxylase, the enzyme catalyzing polyamine synthesis.AMXT 1501 is a polyamine transport inhibitor which prevents uptake of polyamines from the extracellular environment.This trial is being…
Read more